Epigenetics in Cancer
Epigenetics is the study of heritable changes in gene expression that occur without altering the DNA sequence. These changes regulate whether
genes are turned on or off. In cancer, abnormal epigenetic modifications can silence tumor suppressor genes or activate cancer-promoting genes,
contributing to tumor initiation, progression, and resistance to therapy.
Major Epigenetic Mechanisms
1. DNA Methylation
DNA methylation involves the addition of a methyl group (CH₃) to cytosine bases, usually at CpG islands in gene promoter regions.
Normal Function
Regulates normal gene expression.
Maintains genomic stability.
Controls embryonic development and cell differentiation.
In Cancer
Hypermethylation of tumor suppressor gene promoters silences genes that normally prevent cancer.
Hypomethylation can activate oncogenes and increase genomic instability.
Examples
Methylation of genes such as CDKN2A (p16), MLH1, and BRCA1 contributes to several cancers.
2. Histone Modifications
DNA is wrapped around histone proteins to form chromatin. Chemical modifications of histones determine whether DNA is accessible for
transcription.
Common modifications include:
Histone acetylation
Histone deacetylation
Histone methylation
Histone phosphorylation
Histone ubiquitination
Normal Function
Controls chromatin structure.
Regulates gene expression
In Cancer
Loss of histone acetylation often suppresses tumor suppressor genes.
Abnormal histone methylation patterns promote uncontrolled cell growth.
3. Non-Coding RNAs (ncRNAs)
Non-coding RNAs regulate gene expression without producing proteins.
MicroRNAs (miRNAs)
Small RNAs (approximately 22 nucleotides) that bind messenger RNA (mRNA) and inhibit protein production.
Role in Cancer
Some miRNAs function as tumor suppressors.
Others function as oncogenes (oncomiRs
Long Non-Coding RNAs (lncRNAs)
RNAs longer than 200 nucleotides that regulate transcription and chromatin organization.
Role in Cancer
Influence tumor growth.
Promote invasion and metastasis.
Affect response to treatment.
How Epigenetic Changes Contribute to Cancer
Abnormal epigenetic regulation can lead to:
Silencing of tumor suppressor genes
Activation of oncogenes
Increased cell proliferation
Reduced apoptosis (programmed cell death)
Enhanced angiogenesis
Increased invasion and metastasis
Drug resistance
Immune evasion
Epigenetic Biomarkers
Epigenetic alterations are useful as biomarkers because they often occur early during cancer development.
Applications include:
Early cancer detection
Cancer diagnosis
Prognosis
Prediction of treatment response
Monitoring disease recurrence
Examples include methylated DNA detected in blood, urine, or other body fluids through liquid biopsy.
Epigenetic Therapy
Unlike DNA mutations, many epigenetic changes are reversible, making them attractive therapeutic targets.
Current classes of epigenetic drugs include:
DNA Methyltransferase (DNMT) Inhibitors
These drugs reduce abnormal DNA methylation and reactivate silenced tumor suppressor genes.
Examples:
Azacitidine
Decitabine
Used mainly for:
Myelodysplastic syndromes
Acute myeloid leukemia
Histone Deacetylase (HDAC) Inhibitors
These drugs increase histone acetylation, restoring expression of genes that suppress tumor growth.
Examples:
Vorinostat
Romidepsin
Belinostat
Used for selected hematologic malignancies such as certain lymphomas.
Clinical Applications
Epigenetics is increasingly integrated into precision oncology through:
Identification of cancer-specific methylation signatures
Patient stratification for targeted therapies
Monitoring minimal residual disease
Combination therapies with chemotherapy, immunotherapy, and targeted therapy
Development of personalized treatment strategies
Advantages of Epigenetic Biomarkers
Detectable at early stages of cancer
Non-invasive testing through liquid biopsy
Potentially reversible abnormalities
Useful for prognosis and treatment monitoring
Applicable across multiple cancer types
Summary
Epigenetics refers to changes in gene expression without changes to the DNA sequence. In cancer, abnormal DNA methylation, histone modifications,
and non-coding RNA regulation disrupt normal cellular control, leading to uncontrolled growth, metastasis, and treatment resistance.
Because these changes are often reversible, epigenetic biomarkers and therapies have become an important component of modern precision oncology,
improving cancer diagnosis, prognosis, and personalized treatment.
